Bioventus Inc., a leader in active healing innovations, announced a major achievement on July 30, 2025, with the U.S. Food and Drug Administration (FDA) granting 510(k) clearances for its two next-generation Peripheral Nerve Stimulation $(PNS.UK)$ products, TalisMann™ and StimTrial™. These approvals mark a significant milestone for Bioventus, expanding its innovative PNS solutions aimed at chronic pain management. The company plans a limited commercial release in selected U.S. markets during the third quarter, with a broader rollout anticipated in early 2026. This development reinforces Bioventus' commitment to delivering non-opioid, minimally invasive therapies, presenting a substantial growth opportunity in a PNS market projected to exceed $500 million by 2029.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.